%0 Journal Article
%T Engineering a Brighter Future: The Evolving Role of the Pharmacist in the Era of the HeartMate 3
%A Alana M. Ciolek
%A Audrey J. Littlefield
%A Douglas L. Jennings
%J Annals of Pharmacotherapy
%@ 1542-6270
%D 2019
%R 10.1177/1060028018813371
%X Continuous-flow left-ventricular assist devices (CF-LVADs) are an option for patients with end-stage heart failure requiring durable mechanical circulatory support. Two of the older-generation CF-LVADs have been associated with multiple device-related complications, including bleeding and thrombosis. The newest generation CF-LVAD, the HeartMate 3, was engineered specifically to prevent device-related thrombosis. As more data enhance our understanding of the burden of bleeding and thrombotic adverse events, patients with durable mechanical circulatory support may require less-aggressive antithrombotic therapy
%K anticoagulation
%K HeartMate 3
%K hemocompatibility
%K left-ventricular assist device
%U https://journals.sagepub.com/doi/full/10.1177/1060028018813371